The incretin system and cardiometabolic disease
Authors:
- 1 February 2010
- journal article
- review article
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 26 (2) , 87-95
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trialsCurrent Medical Research and Opinion, 2008
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- The Failing Heart — An Engine Out of FuelNew England Journal of Medicine, 2007
- Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trialDiabetes, Obesity and Metabolism, 2007
- The role of gut hormones in glucose homeostasisJournal of Clinical Investigation, 2007
- A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority studyDiabetologia, 2006
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia, 2006
- Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin actionBiochemical and Biophysical Research Communications, 2005
- Glucagon-Like Peptide-1 and Glucose-Dependent Insulin-Releasing Polypeptide Plasma Levels in Response to NutrientsDigestion, 1995